Zion Market Research has published a new report titled “Expression Vectors Market (Bacterial, Yeast, Insect, and Mammalian) by Application (Therapeutic, Research, and Industrial) for Biotechnology & Pharmaceutical Companies, CROs & CMOs, and Academic Research End-user: Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global expression vectors market was valued at approximately USD 240.7 million in 2015 and is expected to reach approximately USD  330.3 million by 2021, growing at a CAGR of around 5.4% between 2016 and 2021.

Expressions vector is the basic tool in biotechnology which is designed for gene expression in cells. The expression vector is used to introduce a specific gene into a target cell. The expression vector can commandeer the target cell’s mechanism for the production of proteins. The cloning vector containing proper expressions signals to have maximum gene expression. Different types of vector system have been developed viz. virus vector, the bacterial vector, plasmid DNA etc.

Browse the full report at https://www.zionmarketresearch.com/report/expression-vectors-market

Global expression vectors market is expected to exhibit strong growth in the near future on account of the rising demand for protein-based drugs. The other key drivers influencing the growth of expression vectors market include genetic disorders, the high prevalence of infectious diseases and other diseases. Moreover, technological advancement in protein expression techniques, molecular biology, and bioinformatics is expected to propel the market growth within the forecast period. Increasing unmet medical needs due to the patent expiration of generic drugs is further projected to drive expression vectors market in order to develop novel drugs. However, high expenditure involved in research employing expression vectors may hamper the market growth in the coming years.

Bacterial, yeast, insect and mammalian expression vectors are available in the global market. In 2015, the bacterial vector was the leading segment due to high transformation levels and simple transformation protocols. The mammalian expression vectors are the key outlet of expression vector market and are expected to witness the fastest growth within the forecast period. Mammalian host systems have the ability to carry out assembly of recombinant proteins, folding, and complex post-translational modifications.

Based on applications the expression vectors market can be segmented into therapeutic, industrial, and research applications. Therapeutic application accounted for the largest market share in 2015 and is expected to remain the fastest growing segment in the years to come. This growth is mainly due to the higher incidence rate of oncology diseases which can be treated by use of expression vectors. Research segment is expected to witness significant growth in the years to come. Technological advancement in proteomics and novel product for protein expression are expected to open up new avenues for the segment growth.

The expression vectors market is segmented on the basis of different end-user such as biotechnology & pharmaceutical companies, contract research organizations (CROs) & contract manufacturing organizations (CMOs), and academic research institutes. Biotechnology & Pharmaceutical companies were the largest segment of expression vectors market in 2015 and are expected to continue its dominance in the near future. This growth is mainly due to the advancement in protein pharmaceuticals synthesis and novel drug using recombinant DNA technology.

The expression vectors market was dominated by North America with the largest share of the total market in 2015. The growth is mainly due to increase scientific research and development of novel technologies in this region. Moreover, high investment of the U.S. private companies in biology research is further expected to fuel the market growth in the years to come.  Moreover, Asia-Pacific market is expected to witness fastest growing region during the forecast period. This growth is mainly due to competitive growth in the pharmaceutical & biotechnology sector coupled with increasing penetration of companies in R&D activities in biotechnology perspective. However, Latin America and the Middle East & Africa are also expected to exhibit significant growth over the forecast period.

Some of the key players including in the expression vectors market such as Promega Corporation, Agilent Technologies, New England Biolabs, Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Merck Millipore, QIAGEN, Clontech Laboratories, Inc., and GenScript USA Inc.